Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study (2022) Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, et al. Journal article The Early Landscape of Immune Cell Subsets in Metastatic NSCLC Patients Treated with Immune Checkpoint Inhibitors (2021) Zhou J, Donaubauer AJ, Frey B, Becker I, Rutzner S, Sun R, Ma H, et al. Conference contribution Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study (2020) Stenzinger A, Endris V, Budczies J, Merkelbach-Bruse S, Kazdal D, Dietmaier W, Pfarr N, et al. Journal article Histology-Depended Pattern of Patho-Histological Response After Induction Therapy in Locally Advanced Non-Small Cell Lung Cancer (2019) Schreiner W, Dudek W, Rieker R, Fietkau R, Sirbu H Conference contribution Treatment Response and Prophylactic Cranial Irradiation Are Important Prognostic Factors in LD SCLC Patients Staged with cMRI (2017) Eze C, Roengvoraphoj O, Niyazi M, Hildebrandt G, Fietkau R, Belka C, Manapov F Conference contribution Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung cancer patients (2015) Koenig K, Peifer M, Fassunke J, Ihle MA, Kuenstlinger H, Heydt C, Stamm K, et al. Journal article ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting (2014) Marx A, Stroebel P, Badve SS, Chalabreysse L, Chan JKC, Chen G, De Leval L, et al. Journal article